Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APVO 
Aptevo Therapeutics Inc (APVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: APVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $21
1 Year Target Price $21
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.71% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.33M USD | Price to earnings Ratio - | 1Y Target Price 21 |
Price to earnings Ratio - | 1Y Target Price 21 | ||
Volume (30-day avg) 1 | Beta 5.87 | 52 Weeks Range 1.32 - 265.81 | Updated Date 10/31/2025 |
52 Weeks Range 1.32 - 265.81 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2680.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -99.45% | Return on Equity (TTM) -437.34% |
Valuation
Trailing PE - | Forward PE 3.94 | Enterprise Value -433519 | Price to Sales(TTM) 1.61 |
Enterprise Value -433519 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 13808966 | Shares Floating 2987928 |
Shares Outstanding 13808966 | Shares Floating 2987928 | ||
Percent Insiders - | Percent Institutions 24.69 |
Upturn AI SWOT
Aptevo Therapeutics Inc
Company Overview
History and Background
Aptevo Therapeutics Inc. was spun out from Emergent BioSolutions in 2016. It focuses on developing novel immuno-oncology therapeutics based on its ADAPTIR and ADAPTIR-FLEX platforms.
Core Business Areas
- ADAPTIR Platform: Aptevo's primary focus is on its ADAPTIR (Modular Protein Technology) platform, which enables the creation of multi-specific biologics for cancer immunotherapy.
- ADAPTIR-FLEX Platform: An improved platform for more potent combination therapies that bind to more than 3 targets.
- Clinical Development: Aptevo is actively involved in clinical trials evaluating its ADAPTIR-based therapies for various cancer types.
Leadership and Structure
Marvin L. White is the President and CEO. The company has a typical biotech structure with departments focused on R&D, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Apex-duet: A bispecific antibody therapeutic candidate designed to activate and redirect T cells to attack cancer cells. It is in clinical development. No current market share, as it's still in development. Competitors: Numerous companies developing bispecific antibodies, including Amgen (AMG), Roche (RHHBY), and Johnson & Johnson (JNJ).
- ALG.APV-527: A bispecific antibody targeting 4-1BB and PD-L1 for solid tumors, currently in preclinical trials. No current market share, as it's still in development. Competitors: Companies developing similar bispecific antibodies in immuno-oncology.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing rapid growth, driven by the increasing prevalence of cancer and the development of novel immunotherapies. The space is highly competitive and dynamic.
Positioning
Aptevo is a smaller player in the immuno-oncology space, focusing on differentiated bispecific antibody therapeutics. Their competitive advantage lies in their ADAPTIR platform, which allows for the creation of novel multi-specific biologics.
Total Addressable Market (TAM)
The global immuno-oncology market is estimated to reach hundreds of billions of dollars. Aptevo, given its early-stage clinical programs, is aiming to capture a portion of this TAM by developing innovative therapies in areas with high unmet need.
Upturn SWOT Analysis
Strengths
- Proprietary ADAPTIR platform
- Potential for novel multi-specific biologics
- Focus on immuno-oncology
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage clinical programs
- Reliance on collaborations and partnerships
- High risk of clinical trial failure
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of ADAPTIR platform to new therapeutic areas
- Advancements in cancer immunotherapy
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in the immuno-oncology landscape
Competitors and Market Share
Key Competitors
- AMGN
- RHHBY
- JNJ
- XOMA
- INBX
Competitive Landscape
Aptevo is a small player in a highly competitive market. Its success depends on differentiating its ADAPTIR-based therapies and securing partnerships with larger companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, driven primarily by preclinical and early clinical development activities.
Future Projections: Future growth depends on the success of clinical trials and potential partnerships.
Recent Initiatives: Focus on advancing clinical programs, expanding ADAPTIR platform, and securing partnerships.
Summary
Aptevo Therapeutics is a small biotech company focused on developing novel immuno-oncology therapies. Its ADAPTIR platform represents a key strength, but it faces significant challenges related to limited resources and clinical trial risks. The company's future depends on successful clinical development and strategic partnerships. It operates in a highly competitive industry and any failures will have a huge effect on the company.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Aptevo Therapeutics Inc. website
- SEC filings
- Industry reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in biotech companies involves significant risks, including the risk of clinical trial failure and the loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptevo Therapeutics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2016-07-20 | President, CEO & Director Mr. Marvin L. White | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://aptevotherapeutics.com |
Full time employees 37 | Website https://aptevotherapeutics.com | ||
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.